嵌合抗原受体T细胞免疫疗法在复发难治非霍奇金淋巴瘤中的应用

Application of chimeric antigen receptor T cell immunotherapy in relapsed/refractory non-Hodgkin lymphoma

目前我国恶性淋巴瘤的发病率逐年上升[1]。虽然随着新的化疗方案、放疗技术、抗CD20单克隆抗体以及一些免疫调节药物的应用,淋巴瘤患者的生存得到了显著提高,但仍有相当一部分患者终因耐药,治疗无效病情进展死亡。

Lymphoma has drawn much attention as one of the most common malignant tumors in China over the past years.With the development of treatment methods including chemotherapy,radiotherapy,hematopoietic stem cell transplantation,molecular targeted drugs and immune agents in the clinical practice,the survival of lymphoma patients has been significantly improved.However,still almost 30% to 40% patients died finally with relapsed/refractory lymphoma.As one of the adoptive cell treatments,Chimeric antigen receptor T-cell(CAR-T)immunotherapy developed rapidly in the past two decades.The remarkable therapeutic efficacy of CAR-T in B-cell line leukemia as well as certain lymphoma subtypes provides potential for treating relapsed/refractory lymphoma.In this review,we will discuss the progress,adverse events,management strategy,limitation and clinical application prospects of CAR-T immunotherapy.